Ismail Hakki Kalkan1, Ferdane Sapmaz2, Sefa Güliter2, Pınar Atasoy3. 1. Department of Gastroenterology, Kırıkkale University Faculty of Medicine, Attar Sokak 21/14 G.O.P., Çankaya, 06700, Ankara, Turkey. drismailster@gmail.com. 2. Department of Gastroenterology, Kırıkkale University Faculty of Medicine, Attar Sokak 21/14 G.O.P., Çankaya, 06700, Ankara, Turkey. 3. Department of Pathology, Kırıkkale University Faculty of Medicine, Ankara, Turkey.
Abstract
BACKGROUND: In several studies, different risk factors other than antibiotic resistance have been documented with Helicobacter pylori eradication failure. We aimed in this study to investigate the relationship of gastric density of H. pylori, the occurrence/degree of gastric atrophy, and intestinal metaplasia (IM) with success rate of H. pylori eradication. METHODS: Two hundred consecutive treatment naive patients who received bismuth containing standart quadruple treatment due to H. pylori infection documented by histopathological examination of two antral or two corpal biopsies entered this retrospective study. The updated Sydney system was used to grade the activity of gastritis, density of H. pylori colonization, atrophy, and IM. Stages III and IV of operative link for gastritis assessment (OLGA) or the operative link on gastric intestinal metaplasia assessment (OLGIM) stages was considered as severe gastritis. H. pylori eradication was determined via stool H. pylori antigen test performed 4 weeks after the end of therapy. RESULTS: The presence of gastric atrophy and IM was significantly higher in patients with eradication failure (p = 0.001 and 0.01, respectively). Severe gastritis (OLGA III-IV and OLGIM III-IV) rates were higher in eradication failure group. A multiple linear regression analysis showed that OLGA and OLGIM stages were to be independent risk factors for eradication failure (p = 0.03 and 0.01, respectively). CONCLUSION: Our results suggested that histopathologically severe gastritis may cause H. pylori eradication failure. In addition, we found that H. pylori density was not a risk factor for treatment failure in patients who receive quadruple treatment.
BACKGROUND: In several studies, different risk factors other than antibiotic resistance have been documented with Helicobacter pylori eradication failure. We aimed in this study to investigate the relationship of gastric density of H. pylori, the occurrence/degree of gastric atrophy, and intestinal metaplasia (IM) with success rate of H. pylori eradication. METHODS: Two hundred consecutive treatment naive patients who received bismuth containing standart quadruple treatment due to H. pyloriinfection documented by histopathological examination of two antral or two corpal biopsies entered this retrospective study. The updated Sydney system was used to grade the activity of gastritis, density of H. pylori colonization, atrophy, and IM. Stages III and IV of operative link for gastritis assessment (OLGA) or the operative link on gastric intestinal metaplasia assessment (OLGIM) stages was considered as severe gastritis. H. pylori eradication was determined via stool H. pylori antigen test performed 4 weeks after the end of therapy. RESULTS: The presence of gastric atrophy and IM was significantly higher in patients with eradication failure (p = 0.001 and 0.01, respectively). Severe gastritis (OLGA III-IV and OLGIM III-IV) rates were higher in eradication failure group. A multiple linear regression analysis showed that OLGA and OLGIM stages were to be independent risk factors for eradication failure (p = 0.03 and 0.01, respectively). CONCLUSION: Our results suggested that histopathologically severe gastritis may cause H. pylori eradication failure. In addition, we found that H. pylori density was not a risk factor for treatment failure in patients who receive quadruple treatment.
Entities:
Keywords:
Atrophy; H. pylori; Intestinal metaplasia; OLGA; OLGIM; Sydney
Authors: Peter Malfertheiner; Francis Megraud; Colm A O'Morain; John Atherton; Anthony T R Axon; Franco Bazzoli; Gian Franco Gensini; Javier P Gisbert; David Y Graham; Theodore Rokkas; Emad M El-Omar; Ernst J Kuipers Journal: Gut Date: 2012-05 Impact factor: 23.059
Authors: F Perri; R Clemente; V Festa; M Quitadamo; P Conoscitore; G Niro; Y Ghoos; P Rutgeerts; A Andriulli Journal: Ital J Gastroenterol Hepatol Date: 1998-04
Authors: H Kashimura; K Suzuki; M Hassan; K Ikezawa; T Sawahata; T Watanabe; A Nakahara; H Mutoh; N Tanaka Journal: Aliment Pharmacol Ther Date: 1999-04 Impact factor: 8.171
Authors: T Furuta; M Sugimoto; N Shirai; F Matsushita; H Nakajima; J Kumagai; K Senoo; C Kodaira; M Nishino; M Yamade; M Ikuma; H Watanabe; K Umemura; T Ishizaki; A Hishida Journal: Aliment Pharmacol Ther Date: 2007-09-01 Impact factor: 8.171
Authors: Petra Bago; Aleksandar Vcev; Monika Tomic; Marjan Rozankovic; Marinko Marusić; Josip Bago Journal: Wien Klin Wochenschr Date: 2007 Impact factor: 1.704